Suppr超能文献

用于分散式、经济高效的基因组监测的Illumina COVIDSeq™ 方案的优化。

Optimization of the Illumina COVIDSeq™ protocol for decentralized, cost-effective genomic surveillance.

作者信息

Carpenter Rob E, Tamrakar Vaibhav K, Almas Sadia, Sharma Aditya, Rowan Chase, Sharma Rahul

机构信息

Advanta Genetics, 10935 CR 159, Tyler, TX, 75703, USA.

University of Texas at Tyler, 3900 University Boulevard, Tyler, TX, 75799, USA.

出版信息

Pract Lab Med. 2023 Mar;34:e00311. doi: 10.1016/j.plabm.2023.e00311. Epub 2023 Feb 1.

Abstract

A decentralized surveillance system to identify local outbreaks and monitor SARS-CoV-2 Variants of Concern is one of the primary strategies for the pandemic's containment. Although next-generation sequencing (NGS) is a gold standard for genomic surveillance and variant discovery, the technology is still cost-prohibitive for decentralized sequencing, particularly in small independent labs with limited resources. We have optimized the Illumina COVIDSeq™ protocol for the Illumina MiniSeq instrument to reduce cost without compromising accuracy. We slashed the library preparation cost by half by using 50% of recommended reagents at each step and normalizing the libraries before pooling to achieve uniform coverage. Reagent-only cost (∼$43.27/sample) for SARS-CoV-2 variant analysis with this normalized input protocol on MiniSeq instruments is comparable to what is achieved on high throughput instruments such as NextSeq and NovaSeq. Using this modified protocol, we tested 153 clinical samples, and 90% of genomic coverage was achieved for 142/153 samples analyzed in this study. The lineage was correctly assigned to all samples (152/153) except for one. This modified protocol can help laboratories with constrained resources to contribute in decentralized COVID-19 surveillance in the post-vaccination era.

摘要

一个用于识别局部疫情爆发并监测严重急性呼吸综合征冠状病毒2(SARS-CoV-2)关注变体的分散式监测系统是疫情防控的主要策略之一。尽管下一代测序(NGS)是基因组监测和变体发现的金标准,但该技术对于分散式测序来说成本仍然过高,尤其是在资源有限的小型独立实验室中。我们针对Illumina MiniSeq仪器优化了Illumina COVIDSeq™方案,以在不影响准确性的前提下降低成本。我们通过在每个步骤使用50%的推荐试剂并在混合前对文库进行归一化处理以实现均匀覆盖,将文库制备成本削减了一半。在MiniSeq仪器上使用这种归一化输入方案进行SARS-CoV-2变体分析的仅试剂成本(约43.27美元/样本)与在NextSeq和NovaSeq等高通量仪器上的成本相当。使用这种改进后的方案,我们测试了153份临床样本,本研究中分析的142/153个样本实现了90%的基因组覆盖。除了一个样本外,所有样本(152/153)的谱系都被正确鉴定。这种改进后的方案可以帮助资源有限的实验室在疫苗接种后的时代为分散式的2019冠状病毒病监测做出贡献。

相似文献

本文引用的文献

5
COVID-19 will continue but the end of the pandemic is near.新冠疫情仍将持续,但大流行已接近尾声。
Lancet. 2022 Jan 29;399(10323):417-419. doi: 10.1016/S0140-6736(22)00100-3. Epub 2022 Jan 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验